Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01913197 · ClinicalTrials.gov registry record · Phase 1
Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy
A Phase 1 study, sponsored by St. Luke's-Roosevelt Hospital Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01913197 is a Phase 1 study that was terminated before completion, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 2 participants.
The verdict
NCT01913197, a Phase 1 study, was terminated before completion, sponsored by St. Luke's-Roosevelt Hospital Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
In standard prostate brachytherapy treatment, the seeds are placed throughout the prostate to treat the entire gland. This is done because, in the past, it was impossible to know where the cancer was located within the prostate. Multiparametric magnetic resonance imaging (MRI) can identify tumor(s) with a high degree of accuracy. This trial will assess whether using MRI to guide prostate brachytherapy can result in less chronic toxicity by allowing lower doses to be delivered to the regions of the prostate without tumor while simultaneously allowing higher doses to the tumor. Subjects enrolled in this study will then be followed over two years and evaluated for toxicity. In addition, after two years they will undergo an MRI and a biopsy to assess the cancer control rate of the treatment.
Interventions
- OTHER An MRI-based technique to identify prostate cancer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01913197
The ClinicalTrials.gov registry entry for NCT01913197 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Luke's-Roosevelt Hospital Center, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which An MRI-based technique to identify prostate cancer is the first listed.
NCT01913197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01913197 about?
NCT01913197 is a clinical study titled "Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy". In standard prostate brachytherapy treatment, the seeds are placed throughout the prostate to treat the entire gland. This is done because, in the past, it was impossible to know where the cancer was located within the prostate. Multiparametric magnetic resonance imaging (MRI) can identify tumor(s) ...
What is the current status of trial NCT01913197?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2013-08. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01913197?
The interventions under investigation include: An MRI-based technique to identify prostate cancer (OTHER).
Who is sponsoring clinical trial NCT01913197?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.